Clinical Trials on Carcinoid

Total 23262 results

University of Western Ontario, Canada

Completed

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Neuroendocrine Carcinoma (Carcinoid)

Canada
Rutgers University

Unknown

An Investigation of Small Intestinal Carcinoid Carcinoma in Families

Carcinoid Carcinoma

United States
National Cancer Institute (NCI)

Completed

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid Tumor

Canada
Rutgers University

Unknown

Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors

Carcinoid Neuroendocrine Cancer

United States
National Cancer Institute (NCI)

Terminated

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Regional Gastrointestinal Carcinoid Tumor | Pulmonary Carcinoid Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

Neuroendocrine Carcinoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid Tumor

United States
Trio Medicines Ltd.
Royal Liverpool University Hospital

Completed

YF476 and Type I Gastric Carcinoids

Hypergastrinaemia | Chronic Atrophic Gastritis | Type I Gastric Carcinoids

United Kingdom
Trio Medicines Ltd.
Norwegian University of Science and Technology

Terminated

YF476 and Type I Gastric Carcinoids (Norway)

Chronic Atrophic Gastritis | Hypergastrinemia | Type I Gastric Carcinoids

Norway
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Gastrointestinal Carcinoid Tumor | Islet Cell Carcinoma
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Neuroendocrine Tumor | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA Syndrome

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Hospices Civils de Lyon

Unknown

Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis (IPOXA)

Peritoneal Carcinosis

France
H. Lee Moffitt Cancer Center and Research Institute
Pharmacyclics LLC.

Completed

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Carcinoid Tumors | Pancreatic NET

United States
University of Alabama at Birmingham

Withdrawn

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

Carcinoid | Neuroendocrine Carcinoma of Pancreas

United States
Institut du Cancer de Montpellier - Val d'Aurelle

Recruiting

Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE) (BCB)

Cancer | Peritoneal Carcinosis

France
Novartis Pharmaceuticals

Completed

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16)

Carcinoma | Neuroendocrine | Advanced and Metastatic Silent Neuro-Endocrine Tumors | Non Functioning Neuroendocrine Tumors (NETs) | Non Syndromic Neuroendocrine Tumors | Carcinoids | Non Functioning

Sweden, Italy, Germany, United Kingdom, Spain, France, Netherlands, Poland
National Institute of Diabetes and Digestive and...

Recruiting

Natural History of Familial Carcinoid Tumor

Carcinoid

United States
European Institute of Oncology

Recruiting

Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications

Neuroendocrine Tumors

Italy
University of Chicago

Withdrawn

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

Neuroendocrine Tumors
Seoul National University Hospital

Completed

RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid (PheoCarcRAD001)

Pheochromocytoma | Extra-adrenal Paraganglioma | Non-functioning Carcinoid

Korea, Republic of
Cylene Pharmaceuticals

Completed

Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

Neuroendocrine Tumors | Carcinoid Tumor

United States
Dana-Farber Cancer Institute
Eli Lilly and Company

Active, not recruiting

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Carcinoid Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals; RECORDATI GROUP

Completed

Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)

Neuroendocrine Tumors | Carcinoid Tumors

United States
University of Western Ontario, Canada

Terminated

Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion

Neuroendocrine Tumors | Carcinoid Tumors

Canada
GERCOR - Multidisciplinary Oncology Cooperative...
Pfizer; Ipsen

Unknown

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors (SUNLAND)

Carcinoid Tumors

France, Belgium
National Cancer Institute (NCI)

Completed

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Metastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Regional Gastrointestinal Carcinoid Tumor

United States
Lale Kostakoglu

Terminated

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Neuroendocrine Tumors | Carcinoid Tumors

United States
Wren Laboratories LLC

Enrolling by invitation

RegisterNET - A Registry for Neuroendocrine Tumors in the USA (RegisterNET)

Neuroendocrine Tumor | Neuroendocrine Carcinoma | Carcinoid

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Pheochromocytoma | Paraganglioma | Carcinoid
Hospices Civils de Lyon

Not yet recruiting

Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors (CRUSOE-NETs)

Carcinoid Heart Disease

France
Yusuf Menda
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Not yet recruiting

A Safety Study of 212Pb-Pentixather Radioligand Therapy

Carcinoid Tumor Lung | Neuroendocrine Tumor of the Lung | Carcinoma, Small-Cell Lung

United States
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Lung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid Tumor

United States
Molecular Insight Pharmaceuticals, Inc.

Withdrawn

Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors

Malignant Carcinoid Tumor
Massachusetts General Hospital

Withdrawn

A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors

Small Bowel Carcinoid Tumor

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Carcinoid Tumor | Neuroendocrine Neoplasm | Metastatic Carcinoid Tumor

United States
King's College Hospital NHS Trust
Advanced Accelerator Applications

Not yet recruiting

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy (CHARRT)

Carcinoid Tumor | Carcinoid Syndrome | Carcinoid Heart Disease
Lexicon Pharmaceuticals

Completed

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Carcinoid Syndrome

United States
Lexicon Pharmaceuticals

Completed

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Carcinoid Syndrome

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Canada, Israel
Boston Medical Center
Amgen

Withdrawn

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Carcinoid Syndrome

United States
Ipsen

Completed

Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain (RECOSY)

Neuroendocrine Tumors

Spain
Centre Hospitalier Universitaire de Saint Etienne

Completed

Endoscopic Treatment of Bronchial Carcinoid Tumors

Carcinoid Tumor

France
Ipsen

Completed

An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome (ELECT)

Carcinoid Syndrome

United States, Turkey, Brazil, India, Ukraine, South Africa, Czechia, Latvia, Poland, Russian Federation, Serbia
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms (TELEPATH)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom
Lexicon Pharmaceuticals

Completed

Telotristat Etiprate for Carcinoid Syndrome Therapy (TELECAST)

Carcinoid Syndrome

United States, Australia, Belgium, Canada, France, Germany, Israel, Spain, Sweden, United Kingdom, Netherlands
Endo Pharmaceuticals

Terminated

Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome

Carcinoid Syndrome

United States
CHU de Quebec-Universite Laval

Recruiting

Personalized PRRT of Neuroendocrine Tumors (P-PRRT)

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Carcinoid Tumor

Canada
Ipsen

Terminated

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome (CAMPANULA)

Carcinoid Syndrome

Spain, Belgium, Ireland, Czechia, Israel, France, United Kingdom, Latvia, Germany, Russian Federation, Slovakia, Italy, Netherlands, Finland, Austria, Poland, Sweden, Ukraine
Ipsen

Terminated

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Malignant Carcinoid Syndrome

United States

Clinical Trials on Carcinoid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations